TheraVectys Is Said to Consider Hong Kong IPO in Rare Move (2)

TheraVectys SAis considering an initial public offering in Hong Kong, according to people familiar with the matter, a rare move for a non-Chinese biotech firm despite a wave of listings in the Asian financial hub.

The France- and US-based immunotherapy company is working with advisers on a potential offering to raise a few hundred million dollars, the people said, asking not to be identified because the deliberations are private. A share sale could take place as soon as this year, the people said.

Considerations are ongoing and no final decisions have been made, they said. A TheraVectys representative declined ...